An operational AI system can remain technically unchanged while the regulatory significance of its output changes materially. The shift occurs downstream, when an output created for operational use begins influencing regulatory evidence. Nothing about the model has to signal that change. The same output can continue through an established process even as the basis on which it should be treated has changed. That makes the handoff difficult to see at the moment when greater assurance may become relevant.
The handoff can be operationally invisible
The execution problem sits in the output’s movement between roles. Before evidentiary influence begins, its relevance is operational. When the output contributes to how regulatory evidence is formed or presented, its role extends beyond its origin. The transition does not require a new AI system or a technical modification. It can arise solely because the output is used differently later in the process. A workflow that continues to recognize the output only by where it came from can miss the change in what that output is now doing.
That distinction changes the assurance question. A system designation such as operational AI describes the original purpose of the technology. It does not, by itself, describe every later use of the output. When evidentiary significance develops after generation, treatment tied only to the original system purpose can become misaligned with the output’s current role. The relevant boundary has moved from the system label to the function the output now performs within the evidence process.
Assurance depends on what the output becomes
The boundary can be difficult to manage through model-focused oversight alone. The point requiring a different level of scrutiny may occur after the AI has already produced its result. Detecting that point depends on visibility into subsequent use. Oversight centered on how the AI was designated when deployed may remain accurate about the system and still fail to capture a later change in the role of its output.
The operational ambiguity does not extend to treating every AI output as regulatory evidence. Most operational outputs can remain operational in effect. The concern starts when a particular use places the AI output within a context that supports regulatory decision-making. That influence may affect analysis or the way evidence is presented in support of regulatory conclusions. The difficult judgment is determining model influence and the appropriate credibility assessment for that context of use.
FDA’s proposed AI credibility framework makes the significance of downstream use more explicit. Model influence depends on how much AI-derived evidence contributes to a decision within a defined context of use. In FDA’s clinical-development example, an AI output used as the sole determinant of whether a participant requires inpatient monitoring has high model influence. In its manufacturing example, independent verification reduces the influence assigned to the AI output. The difference lies in what the output is allowed to determine within the decision process. [1]
That distinction matters because the regulatory issue does not arise from operational AI use alone. It arises when the output’s later function changes while its treatment remains tied to its original purpose. The process can remain consistent with how the technology was initially classified even as the output begins supporting a different kind of decision. The resulting weakness is not visible in the model itself. It appears in the relationship between downstream use and the assurance attached to that use.
Ownership becomes unclear at the evidence boundary
That judgment creates a separate ownership question. Governance of the operational AI does not automatically answer who decides that one of its outputs has crossed into evidentiary use. The model may still sit within the same operational ownership structure, while the output has acquired a role with different regulatory significance. If no explicit technical event marks that transition, responsibility for recognizing it can remain unclear even when responsibility for the underlying AI is well defined. [2]
The result is a decision problem rather than a model-performance problem. The AI may continue functioning exactly as intended. The weakness appears when the process continues applying treatment suited to operational use after evidentiary influence has begun. In that condition, the level of scrutiny attached to the output can lag behind the role the output now plays. The regulatory exposure comes from that mismatch, because weaknesses in the treatment of the output can carry forward into the evidentiary basis supporting regulatory conclusions.
For clinical operations leadership, the point at which a changed context of use is recognized becomes consequential. The unresolved question is not whether the model remains operational AI. Its origin can remain unchanged throughout. The decision concerns whether a specific use of its output has begun shaping regulatory evidence and, if so, when that influence warrants different assurance. Without a visible model change to serve as a marker, the decision rests on the output’s role in the evidence process.
The hardest decision is who calls the transition
Accountability becomes difficult when evidentiary influence may call for a different credibility assessment of an output. Someone must have authority to determine when that event has occurred. Otherwise, the output can acquire regulatory significance before the process formally recognizes the change. The delay is especially difficult to detect because nothing in the AI itself needs to fail or change. Operational treatment can remain internally consistent while becoming inappropriate for the output’s later function.
The most consequential unresolved issue is where that authority sits and what makes its determination binding. Assurance cannot be determined solely by the output’s operational origin once the same output begins shaping regulatory evidence. Leadership is left with a boundary defined by use rather than technical change, and that boundary can carry regulatory significance before it has an obvious operational marker.
Sources:
[1] U.S. Food and Drug Administration. Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance for Industry and Other Interested Parties, January 2025. FDA guidance
[2] Owens K, Griffen Z, Damaraju L. “Managing a ‘responsibility vacuum’ in AI monitoring and governance in healthcare: a qualitative study.” BMC Health Services Research. 2025;25:1217. doi:10.1186/s12913-025-13388-z. PMID: 41023723. PubMed record